: In May 2019, the company’s molecular division, Primerdesign , launched the genesig® q32 qPCR instrument. This next-generation tool was a critical "update" to their hardware lineup, designed to provide faster PCR cycle times.
: On April 30, 2019, the company reported its 2018 results, noting narrowed losses and a focus on double-digit revenue growth. Decoding "SD UPD" novacyy 20190526 sd upd
In early 2019, Novacyt was in a transitional phase. The company was actively streamlining its operations to focus on its high-growth diagnostic products, particularly through its and Lab21 brands. : In May 2019, the company’s molecular division,
: Documentation regarding the hand-over or operational changes during the divestment of their clinical lab units. Decoding "SD UPD" In early 2019, Novacyt was
: Internal database records or software updates for their diagnostic instruments (like the genesig® series).
: Interestingly, Novacyt later acquired Southern Cross Diagnostics (SCD). While that acquisition occurred more recently (early 2026), the initials "SD" frequently appear in their internal supply chain and distribution documentation. The Evolution of Novacyt Post-2019